Patient-specific Boolean models of signalling networks guide personalised treatments
- Barcelona Supercomputing Center (BSC), Spain
- Institut Curie, PSL Research University, France
- RWTH Aachen University, Germany
- Semmelweis University, Hungary
- Astridbio Technologies Ltd, Hungary
- Heidelberg University, Germany
Abstract
Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell-line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell-line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology.
Data availability
Code (and processed data) to reproduce the analyses can be found in a dedicated GitHub (https://github.com/ArnauMontagud/PROFILE_v2), some of the code used in the work can be found in other GitHub repositories (https://github.com/sysbio-curie/PROFILE; https://github.com/sysbio-curie/Logical_modelling_pipeline).The model built can be accessed on the SuppFile1 and on BioModels and GINsim model repositories (https://www.ebi.ac.uk/biomodels/MODEL2106070001; http://ginsim.org/model/signalling-prostate-cancer).
-
GDSC 1 and 2Genomics of Drug Sensitivity in Cancer.
Article and author information
Author details
Julio Saez-Rodriguez
Funding
European Commission (H2020-PHC-668858)
- Arnau Montagud
- Jonas Béal
- Luis Tobalina
- Pauline Traynard
- Vigneshwari Subramanian
- Bence Szalai
- Róbert Alföldi
- László Puskás
- Emmanuel Barillot
- Julio Saez-Rodriguez
- Laurence Calzone
European Commission (H2020-ICT-825070)
- Arnau Montagud
- Alfonso Valencia
European Commission (H2020-ICT-951773)
- Arnau Montagud
- Alfonso Valencia
- Emmanuel Barillot
- Julio Saez-Rodriguez
- Laurence Calzone
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Jennifer Flegg, The University of Melbourne, Australia
Version history
- Preprint posted: July 29, 2021 (view preprint)
- Received: July 30, 2021
- Accepted: January 27, 2022
- Accepted Manuscript published: February 15, 2022 (version 1)
- Version of Record published: April 19, 2022 (version 2)
Copyright
© 2022, Montagud et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,263
- views
-
- 541
- downloads
-
- 41
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Patient-specific Boolean models of signalling networks guide personalised treatments
eLife 11:e72626.
https://doi.org/10.7554/eLife.72626
Further reading
-
- Computational and Systems Biology
- Genetics and Genomics
We propose a new framework for human genetic association studies: at each locus, a deep learning model (in this study, Sei) is used to calculate the functional genomic activity score for two haplotypes per individual. This score, defined as the Haplotype Function Score (HFS), replaces the original genotype in association studies. Applying the HFS framework to 14 complex traits in the UK Biobank, we identified 3619 independent HFS–trait associations with a significance of p < 5 × 10−8. Fine-mapping revealed 2699 causal associations, corresponding to a median increase of 63 causal findings per trait compared with single-nucleotide polymorphism (SNP)-based analysis. HFS-based enrichment analysis uncovered 727 pathway–trait associations and 153 tissue–trait associations with strong biological interpretability, including ‘circadian pathway-chronotype’ and ‘arachidonic acid-intelligence’. Lastly, we applied least absolute shrinkage and selection operator (LASSO) regression to integrate HFS prediction score with SNP-based polygenic risk scores, which showed an improvement of 16.1–39.8% in cross-ancestry polygenic prediction. We concluded that HFS is a promising strategy for understanding the genetic basis of human complex traits.
-
- Computational and Systems Biology
Revealing protein binding sites with other molecules, such as nucleic acids, peptides, or small ligands, sheds light on disease mechanism elucidation and novel drug design. With the explosive growth of proteins in sequence databases, how to accurately and efficiently identify these binding sites from sequences becomes essential. However, current methods mostly rely on expensive multiple sequence alignments or experimental protein structures, limiting their genome-scale applications. Besides, these methods haven’t fully explored the geometry of the protein structures. Here, we propose GPSite, a multi-task network for simultaneously predicting binding residues of DNA, RNA, peptide, protein, ATP, HEM, and metal ions on proteins. GPSite was trained on informative sequence embeddings and predicted structures from protein language models, while comprehensively extracting residual and relational geometric contexts in an end-to-end manner. Experiments demonstrate that GPSite substantially surpasses state-of-the-art sequence-based and structure-based approaches on various benchmark datasets, even when the structures are not well-predicted. The low computational cost of GPSite enables rapid genome-scale binding residue annotations for over 568,000 sequences, providing opportunities to unveil unexplored associations of binding sites with molecular functions, biological processes, and genetic variants. The GPSite webserver and annotation database can be freely accessed at https://bio-web1.nscc-gz.cn/app/GPSite.
